blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2742133

EP2742133 - MPHOSPH1 PEPTIDES AND VACCINES INCLUDING THE SAME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.08.2018
Database last updated on 10.07.2024
FormerThe patent has been granted
Status updated on  01.09.2017
FormerGrant of patent is intended
Status updated on  14.03.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Oncotherapy Science, Inc.
2-1, Sakado 3-chome Takatsu-ku Kawasaki-shi
Kanagawa 213-0012 / JP
[2014/25]
Inventor(s)01 / TSUNODA, Takuya
c/o ONCOTHERAPY SCIENCE INC.
2-1 Sakado 3-chome
Takatsu-ku
Kawasaki-shi Kanagawa 213-0012 / JP
02 / OSAWA, Ryuji
c/o ONCOTHERAPY SCIENCE INC.
2-1 Sakado 3-chome
Takatsu-ku
Kawasaki-shi Kanagawa 213-0012 / JP
03 / YOSHIMURA, Sachiko
c/o ONCOTHERAPY SCIENCE INC.
2-1 Sakado 3-chome
Takatsu-ku
Kawasaki-shi Kanagawa 213-0012 / JP
04 / WATANABE, Tomohisa
c/o ONCOTHERAPY SCIENCE INC.
2-1 Sakado 3-chome
Takatsu-ku
Kawasaki-shi Kanagawa 213-0012 / JP
05 / NAKAMURA, Yusuke
c/o The Institute of Medical Science The Univeristy of Tokyo
6-1 Shirokanedai 4-chome
Minato-ku
Tokyo 108-8639 / JP
 [2014/25]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2017/40]
Former [2014/25]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date12824137.909.08.2012
[2017/40]
WO2012JP05076
Priority number, dateUS201161522991P12.08.2011         Original published format: US 201161522991 P
[2014/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013024582
Date:21.02.2013
Language:EN
[2013/08]
Type: A1 Application with search report 
No.:EP2742133
Date:18.06.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 21.02.2013 takes the place of the publication of the European patent application.
[2014/25]
Type: B1 Patent specification 
No.:EP2742133
Date:04.10.2017
Language:EN
[2017/40]
Search report(s)International search report - published on:JP21.02.2013
(Supplementary) European search report - dispatched on:EP01.06.2015
ClassificationIPC:C12N15/09, A61K38/00, A61P35/00, A61P43/00, C07K7/06
[2014/25]
CPC:
C12N9/93 (EP,US); A61K39/0011 (EP,KR,RU,US); C07K7/06 (KR);
A61K38/08 (KR); A61K39/00 (EP,KR,RU,US); A61P35/00 (EP,KR);
A61P35/02 (EP); A61P37/04 (EP); A61P43/00 (EP);
C07K14/4738 (EP,RU,US); C12N15/8509 (KR); C12N5/0639 (EP,KR,RU,US);
C12N5/10 (EP,US); C12N9/14 (EP,US); C12Y306/04004 (EP,US);
G01N33/505 (EP,US); G01N33/57407 (EP,US); A61K38/00 (EP,US);
C12N2015/8518 (KR); C12N2502/1114 (EP,RU,US); G01N2440/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/25]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MPHOSPH1-PEPTIDE UND DIESE ENTHALTENDE IMPFSTOFFE[2014/25]
English:MPHOSPH1 PEPTIDES AND VACCINES INCLUDING THE SAME[2014/25]
French:PEPTIDES MPHOSPH1 ET VACCINS LES CONTENANT[2014/25]
Entry into regional phase28.02.2014National basic fee paid 
28.02.2014Search fee paid 
28.02.2014Designation fee(s) paid 
28.02.2014Examination fee paid 
Examination procedure28.02.2014Examination requested  [2014/25]
17.12.2015Amendment by applicant (claims and/or description)
03.03.2016Despatch of a communication from the examining division (Time limit: M04)
22.06.2016Reply to a communication from the examining division
21.07.2016Despatch of a communication from the examining division (Time limit: M04)
18.10.2016Reply to a communication from the examining division
15.03.2017Communication of intention to grant the patent
10.07.2017Fee for grant paid
10.07.2017Fee for publishing/printing paid
10.07.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.03.2016
Opposition(s)05.07.2018No opposition filed within time limit [2018/37]
Fees paidRenewal fee
25.08.2014Renewal fee patent year 03
20.08.2015Renewal fee patent year 04
22.08.2016Renewal fee patent year 05
22.08.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.08.2012
AL04.10.2017
CY04.10.2017
CZ04.10.2017
EE04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MK04.10.2017
PL04.10.2017
PT04.10.2017
RO04.10.2017
RS04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
TR04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
[2020/34]
Former [2020/31]HU09.08.2012
CY04.10.2017
CZ04.10.2017
EE04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MK04.10.2017
PL04.10.2017
PT04.10.2017
RO04.10.2017
RS04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
TR04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2020/28]HU09.08.2012
CZ04.10.2017
EE04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
PL04.10.2017
PT04.10.2017
RO04.10.2017
RS04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
TR04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2020/16]CZ04.10.2017
EE04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
TR04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2019/15]CZ04.10.2017
EE04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/52]CZ04.10.2017
EE04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/40]CZ04.10.2017
EE04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SK04.10.2017
SM04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/37]CZ04.10.2017
EE04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
PL04.10.2017
RS04.10.2017
SK04.10.2017
SM04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/24]FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
RS04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/22]FI04.10.2017
LT04.10.2017
NO04.01.2018
Documents cited:Search[XA]WO03064609  (AVENTIS PASTEUR [CA], et al) [X] 1-3,5-16 * sequence 25 *[A] 4
International search[A]WO2006085684  (ONCOTHERAPY SCIENCE INC [JP], et al);
 [X]WO2008047473  (ONCOTHERAPY SCIENCE INC [JP], et al);
 [A]  - NISHIU M ET AL., "Microarray analysis of gene-expression profiles in diffuse large B-cell lymphoma: Identification of genes related to disease progression", JPN. J. CANCER RES., (2002), vol. 93, pages 894 - 901, XP008173524

DOI:   http://dx.doi.org/10.1111/j.1349-7006.2002.tb01335.x
 [AP]  - OBARA W ET AL., "Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.", JAPANESE JOURNAL OF CLINICAL ONCOLOGY, (20120525), vol. 42, no. 7, pages 591 - 600, XP055143328

DOI:   http://dx.doi.org/10.1093/jjco/hys069
by applicantJPS6317688
 US4722848
 US5545807
 US5545806
 US5569825
 US5580859
 US5589466
 US5625126
 US5633425
 US5661016
 US5679647
 WO9804720
 US5736524
 US5739118
 US5804566
 WO9903499
 US5922687
 JPH11510507
 WO9967288
 JP2000509281
 US6150584
 WO2006031221
 WO2006085684
 WO2007032255
 WO2008047473
    - ABAZA A ET AL., J BIOL CHEM, (2003), vol. 278, pages 27844 - 52
    - KAMIMOTO T ET AL., J BIOL CHEM, (2001), vol. 276, pages 37520 - 8
    - KANEHIRA M ET AL., CANCER RES., (20070401), vol. 67, no. 7, pages 3276 - 85
    - BOON T, INT J CANCER, (19930508), vol. 54, no. 2, pages 177 - 80
    - BOON T; VAN DER BRUGGEN P, J EXP MED, (19960301), vol. 183, no. 3, pages 725 - 9
    - HARRIS CC, J NATL CANCER INST, (19961016), vol. 88, no. 20, pages 1442 - 55
    - BUTTERFIELD LH ET AL., CANCER RES, (19990701), vol. 59, no. 13, pages 3134 - 42
    - VISSERS JL ET AL., CANCER RES, (19991101), vol. 59, no. 21, pages 5554 - 9
    - VAN DER BURG SH ET AL., J IMMUNOL, (19960501), vol. 156, no. 9, pages 3308 - 14
    - TANAKA F ET AL., CANCER RES, (19971015), vol. 57, no. 20, pages 4465 - 8
    - FUJIE T ET AL., INT J CANCER, (19990118), vol. 80, no. 2, pages 169 - 72
    - KIKUCHI M ET AL., INT J CANCER, (19990505), vol. 81, no. 3, pages 459 - 66
    - OISO M ET AL., INT J CANCER, (19990505), vol. 81, no. 3, pages 387 - 94
    - BELLI F ET AL., J CLIN ONCOL, (20021015), vol. 20, no. 20, pages 4169 - 80
    - COULIE PG ET AL., IMMUNOL REV, (20021018), vol. 8, pages 33 - 42
    - ROSENBERG SA ET AL., NAT MED, (20040910), no. 9, pages 909 - 15
    - DATE Y ET AL., TISSUE ANTIGENS, (1996), vol. 47, pages 93 - 101
    - KONDO A ET AL., J IMMUNOL, (1995), vol. 155, pages 4307 - 12
    - KUBO RT ET AL., J IMMUNOL, (1994), vol. 152, pages 3913 - 24
    - BENMOHAMED L; KRISHNAN R; LONGMATE J; AUGE C; LOW L; PRIMUS J; DIAMOND DJ, HUM IMMUNOL, (20000806), vol. 1, no. 8, pages 764 - 79
    - VERHOEF ET AL., EUR J DRUG METAB PHARMACOKIN, (1986), vol. 11, pages 291 - 302
    - The Proteins, ACADEMIC PRESS, (1976), vol. 2
    - "peptide synthesis", Development of Pharmaceuticals, HIROKAWA, (1991), vol. 14
    - "Solid Phase Peptide Synthesis", BARANY G.; MERRIFIELD R.B., Peptides, ACADEMIC PRESS, (1980), vol. 2, pages 100 - 118
    - MORRISON J, J BACTERIOLOGY, (1977), vol. 132, pages 349 - 51
    - CLARK-CURTISS; CURTISS ET AL., Methods in Enzymology, (1983), vol. 101, pages 347 - 62
    - BEAUCAGE SL; IYER RP, TETRAHEDRON, (1992), vol. 48, pages 2223 - 311
    - MATTHES ET AL., EMBO J, (1984), vol. 3, pages 801 - 5
    - CANCER RES, (1996), vol. 56, pages 5672 - 7
    - J IMMUNOL, (1998), vol. 161, pages 5607 - 13
    - J EXP MED, (1996), vol. 184, pages 465 - 72
    - MORGAN ET AL., J IMMUNOL, (2003), vol. 171, page 3288
    - KAWAKAMI ET AL., J IMMUNOL., (1989), vol. 142, pages 3452 - 3461
    - K. S. KAWAMURA ET AL., J. IMMUNOL., (2002), vol. 168, pages 5709 - 5715
    - CLIN MICROBIOL REV, (1994), vol. 7, pages 277 - 89
    - DERES ET AL., NATURE, (1989), vol. 342, pages 561 - 4
    - THOMAS KR; CAPECCHI MR, CELL, (1987), vol. 51, pages 503 - 12
    - WOLFF ET AL., SCIENCE, (1990), vol. 247, pages 1465 - 8
    - STOVER ET AL., NATURE, (1991), vol. 351, pages 456 - 60
    - SHATA ET AL., MOL MED TODAY, (2000), vol. 6, pages 66 - 71
    - SHEDLOCK ET AL., J LEUKOC BIOL, (2000), vol. 68, pages 793 - 806
    - HIPP ET AL., IN VIVO, (2000), vol. 14, pages 571 - 85
    - GOLDSPIEL ET AL., CLINICAL PHARMACY, (1993), vol. 12, pages 488 - 505
    - WU; WU, BIOTHERAPY, (1991), vol. 3, pages 87 - 95
    - TOLSTOSHEV, ANN REV PHARMACOL TOXICOL, (1993), vol. 33, pages 573 - 96
    - MULLIGAN, SCIENCE, (1993), vol. 260, pages 926 - 32
    - MORGAN; ANDERSON, ANN REV BIOCHEM, (1993), vol. 62, pages 191 - 217
    - TRENDS IN BIOTECHNOLOGY, (1993), vol. 11, no. 5, pages 155 - 215
    - ALTMAN JD ET AL., SCIENCE, (1996), vol. 274, no. 5284, pages 94 - 6
    - OGG ET AL., SCIENCE, (1998), vol. 279, pages 2103 - 2106
    - ALTMAN ET AL., SCIENCE, (1996), vol. 174, pages 94 - 96
    - CURRENT PROTOCOLS IN IMMUNOLOGY, WILEY/GREENE
    - GALFRE; MILSTEIN, METHODS ENZYMOL, (1981), vol. 73, pages 3 - 46
    - LAMOYI, METHODS ENZYMOL, (1986), vol. 121, pages 652 - 63
    - ROUSSEAUX ET AL., METHODS ENZYMOL, (1986), vol. 121, pages 663 - 9
    - BIRD; WALKER, TRENDS BIOTECHNOL, (1991), vol. 9, pages 132 - 7
    - HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 6
    - FASEB J, (1992), vol. 6, pages 2422 - 7
    - BETTER ET AL., SCIENCE, (1988), vol. 240, pages 1041 - 3
    - LEI ET AL., J BACTERIOL, (1987), vol. 169, page 4379
    - NUCLEIC ACIDS RES, (1990), vol. 18, no. 17, page 5322
    - MULLIGAN ET AL., NATURE, (1979), vol. 277, page 108
    - MIZUSHIMA ET AL., NUCLEIC ACIDS RES, (1990), vol. 18, page 5322
    - PARKER ET AL., J IMMUNOL, (1994), vol. 152, no. 1, pages 163 - 75
    - KUZUSHIMA ET AL., BLOOD, (2001), vol. 98, no. 6, pages 1872 - 81
    - NAKAHARA S ET AL., CANCER RES, (20030715), vol. 63, no. 14, pages 4112 - 8
    - TANAKA H ET AL., BR J CANCER, (20010105), vol. 84, no. 1, pages 94 - 9
    - UMANO Y ET AL., BR J CANCER, (20010420), vol. 84, no. 8, pages 1052 - 7
    - UCHIDA N ET AL., CLIN CANCER RES, (20041215), vol. 10, no. 24, pages 8577 - 86
    - SUDA T ET AL., CANCER SCI, (20060509), vol. 7, no. 5, pages 411 - 9
    - WATANABE T ET AL., CANCER SCI, (20050809), vol. 6, no. 8, pages 498 - 506
    - WALTER EA ET AL., N ENGL J MED, (19951019), vol. 333, no. 16, pages 1038 - 44
    - RIDDELL SR ET AL., NAT MED, (199602), vol. 2, no. 2, pages 216 - 23
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.